Skip to main content
Clinical Trials/NCT03356288
NCT03356288
Completed
Not Applicable

An Observational Proof-of-concept Study to Explore the Waveform Characteristics of Tidal Breathing Carbon Dioxide (CO2), Measured Using the N-Tidal C™ Device, in Different Breathing Conditions.

TidalSense1 site in 1 country70 target enrollmentAugust 9, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asthma
Sponsor
TidalSense
Enrollment
70
Locations
1
Primary Endpoint
The tidal breathing carbon dioxide waveform for each of the breathing conditions as measured by the N-Tidal C device
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study will test the use of a new handheld device (called the N-Tidal C), that measures a person's tidal breath carbon dioxide, in diagnosing the cause of someone's breathlessness. It will also evaluate whether this device can detect when a person's breathing problem is getting worse.

Detailed Description

When a person breathes out, they exhale carbon dioxide (CO2). The CO2 levels in breath change as they breathe out and this makes a specific pattern, or "waveform". This waveform can tell a clinician a lot about the underlying health of a person. There are disease specific CO2 waveforms for common breathing conditions such as Asthma and Chronic Obstructive Pulmonary Disease (COPD). However up until this point there has been no accurate and non-invasive method of measuring the tidal breath CO2 waveform. This study will test the N-Tidal C, a new handheld device that accurately measures this waveform, and whether it can differentiate different causes of breathlessness; namely asthma, heart failure, pneumonia, breathing pattern disorders and motor neurone disease.

Registry
clinicaltrials.gov
Start Date
August 9, 2017
End Date
July 4, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
TidalSense
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Asthma Cohort:
  • A confirmed clinical diagnosis of asthma for ≥ 6months
  • Moderate to severe asthma defined as British Thoracic Society stages 3-5
  • 2 or more exacerbations in the previous 12 months with at least 1 exacerbation within the last 6 months.
  • Exacerbation free for 2 weeks (defined as no increased dose or course of oral corticosteroids or antibiotics).
  • Breathing Pattern Disorder Cohort
  • A Clinical diagnosis of a Breathing Pattern Disorder (BPD)
  • Chronic heart failure Cohort:
  • A confirmed clinical diagnosis of chronic heart failure with both of the following:
  • A Left Ventricular Ejection Fraction \<40% on most recent imaging within the last 12 months.

Exclusion Criteria

  • Known other lung, chest wall, neuromuscular, cardiac or other comorbidity or abnormality that would affect spirometry and/or other measures of lung function or Tidal Breath Carbon Dioxide measurements.
  • In the opinion of the clinical investigator, the participant would have difficulty completing the study procedures consistently over the course of 6 months.

Outcomes

Primary Outcomes

The tidal breathing carbon dioxide waveform for each of the breathing conditions as measured by the N-Tidal C device

Time Frame: 12 months

Secondary Outcomes

  • Hypercapnia in the motor neurone disease patients(12 months)
  • Disease severity in the pneumonia patients(2 days)
  • Usability of the N-Tidal C device(Change measures - baseline to 6 months)
  • Disease Improvement in Breathing Pattern Disorder patients(12 months)
  • Disease Control in asthma patients(12 months)
  • Change in the Tidal Breathing carbon dioxide waveform over time(Change measures - baseline to 6 months)
  • Disease severity in heart failure patients(12 months)
  • Acceptability of the N-Tidal C device(12 months)

Study Sites (1)

Loading locations...

Similar Trials